Table 4.
GEE modelling of initial dose as a response variable
| GEE – Initial dose | ||
|---|---|---|
| Coefficient (95% confidence interval) | P value | |
| Age category | ||
| 18–39 | – | – |
| 40–59 | 0.11 (0.03, 0.18) | 0.00 |
| 50–59 | 0.23 (0.17, 0.30) | 0.00 |
| 60–69 | 0.37 (0.30, 0.43) | 0.00 |
| 70–79 | 0.47 (0.40, 0.53) | 0.00 |
| 80–89 | 0.53 (0.45, 0.60) | 0.00 |
| Sex | ||
| Female | – | – |
| Male | 0.03 (0.01, 0.05) | 0.01 |
| Race | ||
| White | – | – |
| Black or African American | −0.23 (− 0.26, − 0.20) | 0.00 |
| Asian | −0.17 (− 0.23, − 0.11) | 0.00 |
| Other | −0.11 (− 0.16, − 0.05) | 0.00 |
| Unknown | −0.20 (− 0.23, − 0.16) | 0.00 |
| Ethnicity | ||
| Not Hispanic or Latino | – | – |
| Hispanic or Latino | −0.17 (− 0.20, − 0.14) | 0.00 |
| Unknown | 0.03 (0.00, 0.06) | 0.08 |
| Payer | ||
| Commercial | – | – |
| Medicaid | −0.12 (− 0.16, − 0.08) | 0.00 |
| Medicare | −0.05 (− 0.07, − 0.03) | 0.00 |
| Other | 0.01 (− 0.03, 0.04) | 0.69 |
| Cataract | ||
| No cataracts | – | – |
| Cataracts | 0.08 (0.06, 0.10) | 0.00 |
| Glaucoma | ||
| No glaucoma | – | – |
| Glaucoma | −0.05 (− 0.07, − 0.02) | 0.00 |
| Index agent | ||
| Aflibercept | – | – |
| Bevacizumab | −0.20 (− 0.22, − 0.17) | 0.00 |
| Ranibizumab | 0.13 (0.09, 0.16) | 0.00 |
| Baseline visual acuity | ||
| 20/25 or better | – | – |
| Worse than 20/25 − 20/40 | 0.09 0.06, 0.12) | 0.00 |
| Worse than 20/40 − 20/80 | 0.16 (0.13, 0.19) | 0.00 |
| Worse than 20/80 - better than 20/200 | 0.14 (0.10, 0.18) | 0.00 |
| 20/200 or worse | 0.00 (− 0.03, 0.04) | 0.79 |
Abbreviation: GEE Generalized Estimating Equations